IBDEI1N9 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27904,2)
 ;;=^5004069
 ;;^UTILITY(U,$J,358.3,27905,0)
 ;;=G62.0^^109^1392^7
 ;;^UTILITY(U,$J,358.3,27905,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27905,1,3,0)
 ;;=3^Drug-Induced Polyneuropathy
 ;;^UTILITY(U,$J,358.3,27905,1,4,0)
 ;;=4^G62.0
 ;;^UTILITY(U,$J,358.3,27905,2)
 ;;=^5004075
 ;;^UTILITY(U,$J,358.3,27906,0)
 ;;=G62.1^^109^1392^1
 ;;^UTILITY(U,$J,358.3,27906,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27906,1,3,0)
 ;;=3^Alcoholic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,27906,1,4,0)
 ;;=4^G62.1
 ;;^UTILITY(U,$J,358.3,27906,2)
 ;;=^5004076
 ;;^UTILITY(U,$J,358.3,27907,0)
 ;;=G63.^^109^1392^21
 ;;^UTILITY(U,$J,358.3,27907,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27907,1,3,0)
 ;;=3^Polyneuropathy in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,27907,1,4,0)
 ;;=4^G63.
 ;;^UTILITY(U,$J,358.3,27907,2)
 ;;=^5004080
 ;;^UTILITY(U,$J,358.3,27908,0)
 ;;=G70.00^^109^1392^20
 ;;^UTILITY(U,$J,358.3,27908,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27908,1,3,0)
 ;;=3^Myasthenia Gravis w/o Acute Exacerbation
 ;;^UTILITY(U,$J,358.3,27908,1,4,0)
 ;;=4^G70.00
 ;;^UTILITY(U,$J,358.3,27908,2)
 ;;=^329920
 ;;^UTILITY(U,$J,358.3,27909,0)
 ;;=G70.01^^109^1392^19
 ;;^UTILITY(U,$J,358.3,27909,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27909,1,3,0)
 ;;=3^Myasthenia Gravis w/ Acute Exacerbation
 ;;^UTILITY(U,$J,358.3,27909,1,4,0)
 ;;=4^G70.01
 ;;^UTILITY(U,$J,358.3,27909,2)
 ;;=^329921
 ;;^UTILITY(U,$J,358.3,27910,0)
 ;;=G70.80^^109^1392^12
 ;;^UTILITY(U,$J,358.3,27910,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27910,1,3,0)
 ;;=3^Lambert-Eaton Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,27910,1,4,0)
 ;;=4^G70.80
 ;;^UTILITY(U,$J,358.3,27910,2)
 ;;=^340608
 ;;^UTILITY(U,$J,358.3,27911,0)
 ;;=G72.0^^109^1392^6
 ;;^UTILITY(U,$J,358.3,27911,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27911,1,3,0)
 ;;=3^Drug-Induced Myopathy
 ;;^UTILITY(U,$J,358.3,27911,1,4,0)
 ;;=4^G72.0
 ;;^UTILITY(U,$J,358.3,27911,2)
 ;;=^5004095
 ;;^UTILITY(U,$J,358.3,27912,0)
 ;;=G72.41^^109^1392^10
 ;;^UTILITY(U,$J,358.3,27912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27912,1,3,0)
 ;;=3^Inclusion Body Myositis
 ;;^UTILITY(U,$J,358.3,27912,1,4,0)
 ;;=4^G72.41
 ;;^UTILITY(U,$J,358.3,27912,2)
 ;;=^5004098
 ;;^UTILITY(U,$J,358.3,27913,0)
 ;;=G72.49^^109^1392^11
 ;;^UTILITY(U,$J,358.3,27913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27913,1,3,0)
 ;;=3^Inflammatory & Immune Myopathies NEC
 ;;^UTILITY(U,$J,358.3,27913,1,4,0)
 ;;=4^G72.49
 ;;^UTILITY(U,$J,358.3,27913,2)
 ;;=^5004099
 ;;^UTILITY(U,$J,358.3,27914,0)
 ;;=E11.40^^109^1392^5
 ;;^UTILITY(U,$J,358.3,27914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27914,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Neuropathy
 ;;^UTILITY(U,$J,358.3,27914,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,27914,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,27915,0)
 ;;=M54.2^^109^1393^1
 ;;^UTILITY(U,$J,358.3,27915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27915,1,3,0)
 ;;=3^Cervicalgia
 ;;^UTILITY(U,$J,358.3,27915,1,4,0)
 ;;=4^M54.2
 ;;^UTILITY(U,$J,358.3,27915,2)
 ;;=^5012304
 ;;^UTILITY(U,$J,358.3,27916,0)
 ;;=M54.5^^109^1393^3
 ;;^UTILITY(U,$J,358.3,27916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27916,1,3,0)
 ;;=3^Low Back Pain
 ;;^UTILITY(U,$J,358.3,27916,1,4,0)
 ;;=4^M54.5
 ;;^UTILITY(U,$J,358.3,27916,2)
 ;;=^5012311
 ;;^UTILITY(U,$J,358.3,27917,0)
 ;;=M54.9^^109^1393^2
 ;;^UTILITY(U,$J,358.3,27917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27917,1,3,0)
 ;;=3^Dorsalgia,Unspec
 ;;^UTILITY(U,$J,358.3,27917,1,4,0)
 ;;=4^M54.9
 ;;^UTILITY(U,$J,358.3,27917,2)
 ;;=^5012314
 ;;^UTILITY(U,$J,358.3,27918,0)
 ;;=M54.10^^109^1393^19
